Cheson heads Lymphoma Research Foundation board

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 7
Volume 19
Issue 7

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Dr. Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies. He currently serves as editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia and Clinical Advances in Hematology and Oncology.

The 40-member scientific board develops the foundation's research portfolio, reviews grant proposals, and makes recommendations about research priorities and funding to the New York-based foundation's board of directors.

Dr. Cheson serves on the Oncology News International editorial advisory board.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Related Content